Cybin to Commence Trading on the NYSE American on August 5
04 August 2021 - 4:00PM
InvestorsHub NewsWire
TORONTO, Canada -- August 4, 2021 -- InvestorsHub NewsWire
-- Cybin Inc. (NEO:CYBN)
(OTCQB:CLXPF)
("Cybin" or the "Company"), a
biotechnology company focused on progressing psychedelic
therapeutics, today announced that its common shares will open for
trading on the NYSE American LLC stock exchange ("NYSE
American") on August 5, 2021, under the
symbol "CYBN".
In addition to listing and trading on the NYSE American in U.S.
dollars, Cybin's common shares will continue to be listed and trade
in Canada on the NEO Exchange ("NEO") in Canadian
dollars under the symbol "CYBN".
Shareholders that purchased their Cybin common shares
"over-the-counter" or OTC, including shareholders whose shares are
denoted in their institution/broker account with the symbol
"CLXPF", are advised to monitor their account to ensure their
holdings are updated to reflect the NYSE American listing and
trading symbol, as the Company expects OTC quotations for Cybin's
common shares to cease in connection with the NYSE American
listing. Shareholders are advised to contact their broker for more
information if they have questions in this regard.
Cybin's common shares will also continue to trade on the
Frankfurt Stock Exchange under the symbol "R7E1".
About Cybin
Cybin is a leading biotechnology company focused on progressing
psychedelic therapeutics by utilizing proprietary drug discovery
platforms, innovative drug delivery systems, novel formulation
approaches and treatment regimens for psychiatric disorders.
Cautionary Notes and Forward-Looking
Statements
Certain statements in this news release related to the Company
are forward-looking statements and are prospective in nature.
Forward-looking statements are not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "may", "should", "could", "intend",
"estimate", "plan", "anticipate", "expect", "believe" or
"continue", or the negative thereof or similar variations.
Forward-looking statements in this news release include statements
regarding the commencement of trading on the NYSE American, the
continued listing on the NEO, the cease of quotation on the OTC
markets and the continued trading on the Frankfurt Stock Exchange.
There are numerous risks and uncertainties that could cause actual
results and Cybin's plans and objectives to differ materially from
those expressed in the forward-looking information. Actual results
and future events could differ materially from those anticipated in
such information. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend to update these forward-looking
statements.
Cybin makes no medical, treatment or health benefit claims about
Cybin's proposed products. The U.S. Food and Drug Administration,
Health Canada or other similar regulatory authorities have not
evaluated claims regarding psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds or
nutraceutical products. The efficacy of such products have not been
confirmed by approved research. There is no assurance that the use
of psilocybin, psychedelic tryptamine, tryptamine derivatives or
other psychedelic compounds or nutraceuticals can diagnose, treat,
cure or prevent any disease or condition. Vigorous scientific
research and clinical trials are needed. Cybin has not conducted
clinical trials for the use of its proposed products. Any
references to quality, consistency, efficacy and safety of
potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on Cybin's
performance and operations.
The NEO Exchange has neither approved nor disapproved the
contents of this news release and is not responsible for the
adequacy and accuracy of the contents herein.
Contacts
Investor Contacts:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com
Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com
Media Contact:
John Kanakis
Cybin Inc.
John@cybin.com
Cybin (NEO:CYBN)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Cybin (NEO:CYBN)
Historical Stock Chart
Von Mai 2023 bis Mai 2024